Compare VNRX & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | CLGN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 33.8M |
| IPO Year | N/A | N/A |
| Metric | VNRX | CLGN |
|---|---|---|
| Price | $0.28 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.17 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 2.6M | 16.9K |
| Earning Date | 11-13-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,472,007.00 | ★ $2,475,000.00 |
| Revenue This Year | $55.33 | $1,617.28 |
| Revenue Next Year | $493.79 | $83.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.48 | ★ 280.77 |
| 52 Week Low | $0.27 | $1.31 |
| 52 Week High | $0.94 | $4.98 |
| Indicator | VNRX | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.86 | 36.71 |
| Support Level | $0.28 | $1.77 |
| Resistance Level | $0.34 | $2.08 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 11.30 | 16.67 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.